Crossmark

Perianal fistulizing Crohn’s disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies

Published Online: 2024-02-03

Published Print: 2024-02

Authors

Devi, Jalpa

Ballard, David H.

Aswani-Omprakash, Tina

Parian, Alyssa M.

Deepak, Parakkal http://orcid.org/0000-0002-3436-9784
License Information

Text and Data Mining valid from 2024-02-01

Version of Record valid from 2024-02-01
More Information

Article History

Received: 20 November 2023

Accepted: 2 January 2024

First Online: 3 February 2024

Declarations

:

: NA.

: NA.

: Jalpa Devi: no relevant conflicts of interest exist. David H. Ballard: research support from an Investigator-Initiated Study from Takeda Pharmaceuticals. Tina-Aswani Omprakash: no relevant conflicts of interest exist. Alyssa M. Parian: no relevant conflicts of interest exist. Parakkal Deepak: consultant or on an advisory board for Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, CorEvitas LLC and Scipher Medicine Corporation. He has also received funding under a sponsored research agreement unrelated to the data in the paper from Takeda Pharmaceutical, Arena Pharmaceuticals, Bristol Myers Squibb-Celgene and Boehringer Ingelheim.

: The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or the printer/publishers are responsible for the results/findings and content of this article.

Document is current